Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference in Belfast, Northern Ireland(1).

Tuberous sclerosis complex is a genetic disorder that may cause non-cancerous tumors to form in vital organs, including the brain (SEGAs) and kidney (angiomyolipomas)(3). These kidney tumors occur in up to 80% of patients, usually occurring between the ages of 15 and 30 and increasing in prevalence with age(2,3). Angiomyolipomas are the greatest cause of morbidity and mortality in adult TSC patients, as larger tumors may cause severe bleeding, require surgical intervention or result in kidney failure(2,3). Tumor symptoms may include nausea, vomiting, pain and bleeding(3,6,7).

Results of the 118-patient, randomized, placebo-controlled Phase III EXIST-2 (EXamining everolimus In a Study of TSC) trial showed 42% of patients (33 of 79) experienced a response in the everolimus arm versus 0% of patients (0 of 39) on placebo (p<0.0001) based on best overall response rate(1). These results add to the recent positive Phase III data from a separate trial in patients with TSC, which demonstrated reduction in the size of non-cancerous brain tumors (SEGAs) with everolimus(5).

"For the first time, a large placebo-controlled study has focused specifically on angiomyolipomas in TSC patients, an area with clear unmet need," said Dr. John Bissler, lead study author and Clark D. West Endowed Chair of Nephrology at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. "In addition to the tumor reduction seen with everolimus in this trial, s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... May 21, 2013  LCA-Vision Inc. (NASDAQ: LCAV ... the Lasik Plus ® brand, announces that all nominees to ... at today,s annual meeting of stockholders.  These Directors are: ... President of Bahl & Gaynor Investment Counsel , ... , Edgar F. Heizer III , ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
... VILLAGE, Colo. , June 28 Recondo ... the healthcare industry, announced today the general availability of ... and disparate hospital systems, applications, software services, and databases. ... developed decades ago, hospitals have been forced to deploy ...
... 28 Reportlinker.com announces that a new market research report is available in its ... Global Melanoma Therapeutics industry , ... http://www.reportlinker.com/p0197206/Global-Melanoma-Therapeutics-industry.html , ... analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive ...
Cached Medicine Technology:Recondo Technology Announces Integration Initiative for US Hospital Systems 2Recondo Technology Announces Integration Initiative for US Hospital Systems 3Recondo Technology Announces Integration Initiative for US Hospital Systems 4Global Melanoma Therapeutics Industry 2Global Melanoma Therapeutics Industry 3Global Melanoma Therapeutics Industry 4Global Melanoma Therapeutics Industry 5Global Melanoma Therapeutics Industry 6Global Melanoma Therapeutics Industry 7Global Melanoma Therapeutics Industry 8Global Melanoma Therapeutics Industry 9Global Melanoma Therapeutics Industry 10Global Melanoma Therapeutics Industry 11Global Melanoma Therapeutics Industry 12
(Date:5/22/2013)... 22, 2013 In partnership with ... Surge, LLC, E-Dentists.com has launched a new SEO ... feature numerous topics of interest to dentists and ... dental health. , http://www.E-Dentists.com/Blog/ , Blogging ... marketing. In addition to addressing keyword placement and ...
(Date:5/22/2013)... May 22, 2013 Teams who focus ... improvements use the new Do-Done StepTracker whiteboard as a ... the Do-Done board to display the current status of ... production cells and departments is listed down the side ... start a project, the squares are filled with yellow ...
(Date:5/22/2013)... MA New research from Brigham and Women,s Hospital ... fibrosis, an uncommon but deadly lung disease, may be ... These findings will be presented at the American ... the New England Journal of Medicine on ... 2013 print edition., "While this variant of the MUC5B ...
(Date:5/22/2013)... John Mathews from the University of Melbourne said this ... the undoubted benefits from CT scans in diagnosing and ... the British Medical Journal today and involved ... and the International Agency for Research on Cancer in ... were very useful in providing detailed three dimensional pictures ...
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
Breaking Medicine News(10 mins):Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:Registry questions superiority of bivalirudin over heparin 2
... study has found that Hypnotherapy can be used to relieve ... ,In a small study researchers randomly divided 28 patients ... group received 12 sessions of hypnotherapy over 17 weeks while ... placebo or dummy medicine. , ,According to the BMJ, ...
... Endocrinologists (AACE) Fifteenth Annual Meeting and Clinical Congress to ... 26-30 will discuss important benefits //of vitamin D and ... ,Vitamin D has been in the new ... has been attributed to it. Recent studies have highlighted ...
... According to a large study by Boston University, Black women ... greater risk of breast cancer.// ,The study was published ... Medicine., ,This study is unique because there are previous ... and so it would benefit. ,Lead researcher Dr. Lynn ...
... Madhya Pradesh fell ill after feasting at a marriage dinner, ... police said Thursday. // ,While 65 affected people ... after first aid, a hospital spokesman said. ,Earlier, ... feast. ,While many of those admitted to hospital ...
... have found a link between diet and ALS saying ... progression of Amyotrophic Lateral Sclerosis (ALS). // The Mount ... a correlation between diet and neuronal cell death, the ... an adult-onset neurodegenerative disorder in which spinal and cortical ...
... funded the sex-swap surgery of a former sailor is now ... Bainbridge, 57, from Middleton, says she needs the ?2,500 laser ... wear sleevless dresses in the summer. ,Middleton and ... is waiting for a date for surgery at Charing Cross ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: